American Industrial Partners to Acquire Avanos Medical for $1.27 Billion

Avanos Medical, Inc. (AVNS) entered a merger agreement on April 14, 2026, to be acquired by affiliates of American Industrial Partners in a deal valued at $1.27 billion.

Deal Structure:

Avanos stockholders will receive $25 per share in cash for each share of common stock they own, representing a premium of 72.06% from the stock’s last close.

Company Profile:

Avanos is a medical device company that develops and sells products for digestive health, respiratory care, and non-opioid pain management across global markets. It primarily serves hospitals and healthcare providers with chronic care and surgical recovery solutions.

American Industrial Partners is a private equity firm with roughly $17.5 billion in assets under management that invests in industrial and engineered products businesses through buyouts, divestitures, and recapitalizations.

Deal Details and Timeline:

The deal is expected to close in the second half of 2026.

Avanos will continue to maintain its headquarters in Alpharetta, Georgia.

J.P. Morgan Securities is the main financial advisor to Avanos, and Alston & Bird is its legal advisor. UBS Investment Bank also provided financial advice. For AIP, Sidley Austin is acting as legal advisor.

American Industrial Partners is purchasing Avanos at 21.78 times its EBITDA.

Deal Metrics:

For more detailed information about this merger and acquisition, please visit the Deal Metrics page:

Deal Metrics for the acquisition of Avanos Medical, Inc. (AVNS) by American Industrial Partners

The Deal Metrics page provides comprehensive insights, including:

• A spread history chart of the merger from announcement through eventual completion or failure.
• A timeline of events as the merger progresses, including HSR period expiration, regulatory approvals, shareholder votes, etc.
• News and SEC filings related to the merger.
• A history of deal updates.
• And much more.

Disclaimer: Please do your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article